2026​

57. Lee SM, Lee MS, Jung HR, Lee J, Cho B, Jin W, Moon MH, Shin N, Han SH, Choi DS, Lee B, Hong SP, Kim JI, Lim CS, Cho SY*, Choi JW*, Lee JP*. Therapeutic Potential of HSP90 Inhibitor 17-DMAG in Regulating METTL3 for Kidney Fibrosis Treatment. J Am Soc Nephrol. 2026 Jan 26.

​

2025

56. Park SB, Kim H, Oh Y, Jin M, Jeon M, Kim Y, Park T, Kim J, Cho B, Noh C, Cho J, Lee JH, Jeong C, Mok JW, Eom SH, Cho SY*, Park H*, Kim YC*. Discovery of (4-Phenyl-cyclohexyl)acetate-Derived Tyrosylprotein Sulfotransferase 2 (TPST2) Inhibitors with Potent Anti-Tumor Activity for Immuno-Oncology Applications. J Med Chem. 2025 Nov 13;68(21):22401-22427

​​

55. Cho Y, Lee SE, Oh J, Jang D, Shin S, Lee SJ, Kim J, Yang Y, Kim D, Jung HR, Oh Y, Park YB, Choi JM, Cho SY*. Comprehensive profiling of RNA modification-related genes identifies RNA m7G binding protein CBP20 as a therapeutic target for tumor growth inhibition. Exp Mol Med. 2025 Sep;57(9):1978-1995.

​

54. Ryu Y, Chang E, Park H, Cho SY*, An JY*. Proteogenomic Analysis on RNA m6A Modification-Associated Genes Identifies a Distinct Subgroup with High IGF2BPs Expression Across Cancer Types. Int J Med Sci. 2025 Aug 16;22(15):3815-3827.

​

53. Jeong D, Park SH, Kim J, Kim H, Jang Y, Koh J, Jeon YK, Tasaki T, Kwon YT*, Han D*, Cho SY*, Lee MJ*. Tumor-promoting UBR4 coordinates impaired mitophagy-associated senescence and lung adenocarcinoma pathogenesis. Proc Natl Acad Sci U S A. 2025 Jun 24;122(25):e2425015122.

​

2024​

52. Jang D, Hwa C, Kim S, Oh J, Shin S, Lee SJ, Kim J, Lee SE, Yang Y, Kim D, Lee S, Jung HR, Oh Y, Kim K, Lee HS, An JY*, Cho SY*. RNA N6-Methyladenosine-Binding Protein YTHDFs Redundantly Attenuate Cancer Immunity by Downregulating IFN-γ Signaling in Gastric Cancer. Adv Sci (Weinh). 2025 Jan;12(3):e2410806.​

​​

51. Oh Y, Kim S, Kim Y, Kim H, Jang D, Shin S, Lee SJ, Kim J, Lee SE, Oh J, Yang Y, Kim D, Jung HR, Kim S, Kim J, Min K, Cho B, Seo H, Han D, Park H*, Cho SY*. Genome-wide CRISPR screening identifies tyrosylprotein sulfotransferase-2 as a target for augmenting anti-PD1 efficacy. Mol Cancer. 2024 Aug 2;23(1):155.

​​

50. Lee CR, Suh J, Jang D, Jin BY, Cho J, Lee M, Sim H, Kang M, Lee J, Park JH, Lee KH, Hwang GS, Moon KC, Song C, Ku JH, Kwak C, Kim HH, Cho SY*, Choi M*, Jeong CW*. Comprehensive molecular characterization of TFE3-rearranged renal cell carcinoma. Exp Mol Med. 2024 Aug;56(8):1807-1815.

​​

49. Oh SY, Jang G, Kim J, Jeong KY, Kim HM, Kwak YJ, Kong SH, Park DJ, Lee HJ, Cho SY, Kim JI, Yang HK*. Identification of New Pathogenic Variants of Hereditary Diffuse Gastric Cancer. Cancer Res Treat. 2024 Oct;56(4):1126-1135.

 

48. Jung HR, Lee J, Hong SP, Shin N, Cho A, Shin DJ, Choi JW, Kim JI, Lee JP*, Cho SY*. Targeting the m6A RNA methyltransferase METTL3 attenuates the development of kidney fibrosis. Exp Mol Med. 2024 Feb;56(2):355-369.

 

47. Lee Y, Jang HR, Lee D, Lee J, Jung HR, Cho SY*, Lee HY*. Graphislactone A, a Fungal Antioxidant Metabolite, Reduces Lipogenesis and Protects against Diet-Induced Hepatic Steatosis in Mice. Int J Mol Sci. 2024 Jan 16;25(2):1096.

​​

2023

46. Lee SJ, Shin JW, Kwon MA, Lee KB, Kim HJ, Lee JH, Kang HS, Jun JK, Cho SY*, Kim IG*. Transglutaminase 2 Prevents Premature Senescence and Promotes Osteoblastic Differentiation of Mesenchymal Stem Cells through NRF2 Activation. Stem Cells Int. 2023 Oct 20;2023:8815888.

 

45. Kim Y, Shin S, Kwon S, Moon K, Baek SV, Jo A, Kim HS, Hwang GH, Bae S, Kim YH*, Cho SY*, Oh JM*. METTL3 regulates alternative splicing of cell cycle-related genes via crosstalk between mRNA m6A modifications and splicing factors. Am J Cancer Res. 2023 Apr 15;13(4):1443-1456.

​

2022

44. Jung HR, Oh Y, Jang D, Shin S, Lee SJ, Kim J, Lee SE, Oh J, Jang G, Kwon O, Lee Y, Lee HY, Cho SY*. Gut bacteria-derived 3-phenylpropionylglycine mitigates adipocyte differentiation of 3T3-L1 cells by inhibiting adiponectin-PPAR pathway. Genes Genomics. 2023 Jan;45(1):71-81.

 

43. Jang G, Oh J, Jun E, Lee J, Kwon JY, Kim J, Lee SH, Kim SC, Cho SY*, Lee C*. Direct cell-to-cell transfer in stressed tumor microenvironment aggravates tumorigenic or metastatic potential in pancreatic cancer. NPJ Genom Med. 2022 Oct 27;7(1):63.

 

42. Oh J, Hwa C, Jang D, Shin S, Lee SJ, Kim J, Lee SE, Jung HR, Oh Y, Jang G, Kwon O, An JY*, Cho SY*. Augmentation of the RNA m6A reader signature is associated with poor survival by enhancing cell proliferation and EMT across cancer types. Exp Mol Med. 2022 Jul;54(7):906-921.

​

2021 

41. Na D, Chae J, Cho SY, Kang W, Lee A, Min S, Kang J, Kim MJ, Choi J, Lee W, Shin D, Min A, Kim YJ, Lee KH, Kim TY, Suh YS, Kong SH, Lee HJ, Kim WH, Park H, Im SA*, Yang HK*, Lee C*, Kim JI*. Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts. Nat Commun. 2021 Aug 10;12(1):4840.

 

40. Jeong D, Kim HS, Kim HY, Kang MJ, Jung H, Oh Y, Kim D, Koh J, Cho SY, Jeon YK, Lee EB, Lee SH, Shin EC, Kim HM, Yi EC, Chung DH*. Soluble Fas ligand drives autoantibody-induced arthritis by binding to DR5/TRAIL-R2. Elife. 2021 Jul 5;10:e48840.

​

39. Jung HR, Oh Y, Na D, Min S, Kang J, Jang D, Shin S, Kim J, Lee SE, Jeong EM, An JY, Sung CO, Lee WS, Lee C, Cho SY*. CRISPR screens identify a novel combination treatment targeting BCL-XL and WNT signaling for KRAS/BRAF-mutated colorectal cancers. Oncogene. 2021 May;40(18):3287-3302.

​

38. Lee SH, Cho SY, Yoon Y, Park C, Sohn J, Jeong JJ, Jeon BN, Jang M, An C, Lee S, Kim YY, Kim G, Kim S, Kim Y, Lee GB, Lee EJ, Kim SG, Kim HS, Kim Y, Kim H, Yang HS, Kim S, Kim S, Chung H, Moon MH, Nam MH, Kwon JY, Won S, Park JS, Weinstock GM, Lee C, Yoon KW*, Park H*. Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice. Nat Microbiol. 2021 Mar;6(3):277-288.

​

37. Kim HJ, Lee JH, Cho SY, Jeon JH, Kim IG*. Transglutaminase 2 mediates transcriptional regulation through BAF250a polyamination. Genes Genomics. 2021 Apr;43(4):333-342.

​

36. Oh Y, Jung HR, Min S, Kang J, Jang D, Shin S, Kim J, Lee SE, Sung CO, Lee WS, Lee C, Jeong EM*, Cho SY*. Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-XL inhibitor ABT-263 in KRAS-mutant colorectal cancers. Cancer Lett. 2021 Jan 28;497:123-136.

​

35. Kim HJ, Lee JH, Lee KB, Shin JW, Kwon MA, Lee S, Jeong EM, Cho SY, Kim IG*. Transglutaminase 2 crosslinks the glutathione S-transferase tag, impeding protein-protein interactions of the fused protein. Exp Mol Med. 2021 Jan;53(1):115-124.

​

2020

34. Cho SY*. Patient-derived xenografts as compatible models for precision oncology. Lab Anim Res. 2020 May 20;36:14.

​

33. Lee J, Choi A, Cho SY, Jun Y, Na D, Lee A, Jang G, Kwon JY, Kim J, Lee S*, Lee C*. Genome-scale CRISPR screening identifies cell cycle and protein ubiquitination processes as druggable targets for erlotinib-resistant lung cancer. Mol Oncol. 2021 Feb;15(2):487-502.

​

32. Choi A, Jang I, Han H, Kim MS, Choi J, Lee J, Cho SY, Jun Y, Lee C, Kim J, Lee B*, Lee S. iCSDB: an integrated database of CRISPR screens. Nucleic Acids Res. 2021 Jan 8;49(D1):D956-D961.

​

31. Park S, Kim TM*, Cho SY*, Kim S, Oh Y, Kim M, Keam B, Kim DW, Heo DS. Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells. Cancer Lett. 2020 Dec 28;495:135-144.

​

30. Kim JW, Cho SY, Chae J, Kim JW, Kim TY, Lee KW, Oh DY, Bang YJ, Im SA*. Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer. Cancer Res Treat. 2020 Oct;52(4):1178-1187.

​

29. Cho SY*, Oh Y, Jeong EM, Park S, Lee D, Wang X, Zeng Q, Qin H, Hu F, Gong H, Liu X, Zhang G, Na D, Lee J, Chae J, Suh YS, Kong SH, Lee HJ, Kim JI, Park H, Zhang C, Yang HK*, Lee C*. Amplification of transglutaminase 2 enhances tumor-promoting inflammation in gastric cancers. Exp Mol Med. 2020 May;52(5):854-864.

​

28. Cho SY*, Lee S, Yeom J, Kim HJ, Lee JH, Shin JW, Kwon MA, Lee KB, Jeong EM, Ahn HS, Shin DM, Kim K*, Kim IG*. Transglutaminase 2 mediates hypoxia-induced selective mRNA translation via polyamination of 4EBPs. Life Sci Alliance. 2020 Feb 19;3(3):e201900565.

​

2019

27. Cho SY, Chae J, Na D, Kang W, Lee A, Min S, Kang J, Choi B, Lee J, Sung CO, Chuang JH, Lee C, Lee WS*, Park H*, Kim JI*. Unstable Genome and Transcriptome Dynamics during Tumor Metastasis Contribute to Therapeutic Heterogeneity in Colorectal Cancers. Clin Cancer Res. 2019 May 1;25(9):2821-2834.

​

2018

26. Jeong TD, Cho SY, Kim MW, Huh J*. Significant allelic dropout phenomenon of Oncomine BRCA Research Assay on Ion Torrent S5. Clin Chem Lab Med. 2019 May 27;57(6):e124-e127.

​

25. Cho SY*, Sung CO, Chae J, Lee J, Na D, Kang W, Kang J, Min S, Lee A, Kwak E, Kim J, Choi B, Kim H, Chuang JH, Pak HK, Park CS, Park S, Ko YH, Lee D, Roh J, Cho MS, Park S, Ju YS, Suh YS, Kong SH, Lee HJ, Keck J, Banchereau J, Liu ET, Kim WH, Park H, Yang HK, Kim JI*, Lee C*. Alterations in the Rho pathway contribute to Epstein-Barr virus-induced lymphomagenesis in immunosuppressed environments. Blood. 2018 Apr 26;131(17):1931-1941.

​

24. Jeong EM, Yoon JH, Lim J, Shin JW, Cho AY, Heo J, Lee KB, Lee JH, Lee WJ, Kim HJ, Son YH, Lee SJ, Cho SY, Shin DM*, Choi K*, Kim IG*. Real-Time Monitoring of Glutathione in Living Cells Reveals that High Glutathione Levels Are Required to Maintain Stem Cell Function. Stem Cell Reports. 2018 Feb 13;10(2):600-614.

​

2017

23. Cho SY, Han JY, Na D, Kang W, Lee A, Kim J, Lee J, Min S, Kang J, Chae J, Kim JI, Park H*, Lee WS*, Lee C*. A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers. Mol Cancer Ther. 2017 Oct;16(10):2178-2190.

​

22. Cho SY, Park C, Na D, Han JY, Lee J, Park OK, Zhang C, Sung CO, Moon HE, Kim Y, Kim JH, Kim JJ, Khang SK, Nam DH, Choi JW, Suh YL, Kim DG, Park SH, Youn H, Yun K, Kim JI, Lee C, Paek SH*, Park H*. High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients. Exp Mol Med. 2017 Apr 14;49(4):e317

​

2016

21. Jeong EM, Son YH, Choi Y, Kim JH, Lee JH, Cho SY, Kim IG*. Transglutaminase 2 is dispensable but required for the survival of mice in dextran sulfate sodium-induced colitis. Exp Mol Med. 2016 Nov 4;48(11):e267.

​

20. Cho SY*, Kang W, Han JY, Min S, Kang J, Lee A, Kwon JY, Lee C*, Park H*. An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts. Mol Cells. 2016 Feb;39(2):77-86.

​

2015

19. Park H, Cho SY, Kim H, Na D, Han JY, Chae J, Park C, Park OK, Min S, Kang J, Choi B, Min J, Kwon JY, Suh YS, Kong SH, Lee HJ, Liu ET, Kim JI, Kim S, Yang HK, Lee C*. Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer. Proc Natl Acad Sci U S A. 2015 Oct 6;112(40):12492-7.

​​

18. Cho SY, Lee JH, Ju MK, Jeong EM, Kim HJ, Lim J, Lee S, Cho NH, Park HH, Choi K, Jeon JH, Kim IG*. Cystamine induces AIF-mediated apoptosis through glutathione depletion. Biochim Biophys Acta. 2015 Mar;1853(3):619-31.

​

2014

17. Lee JH, Jeong J, Jeong EM, Cho SY, Kang JW, Lim J, Heo J, Kang H, Kim IG, Shin DM*. Endoplasmic reticulum stress activates transglutaminase 2 leading to protein aggregation. Int J Mol Med. 2014 Apr;33(4):849-55.

​

16. Min SK, Min SI, Jeong EM, Cho SY, Ha J, Kim SJ, Kim IG*. Intimal hyperplasia in loop-injured carotid arteries is attenuated in transglutaminase 2-null mice. J Korean Med Sci. 2014 Mar;29(3):363-9.

​

2012

15. Cho SY, Jeong EM, Lee JH, Kim HJ, Lim J, Kim CW, Shin DM, Jeon JH, Choi K, Kim IG*. Doxorubicin induces the persistent activation of intracellular transglutaminase 2 that protects from cell death. Mol Cells. 2012 Mar;33(3):235-41.

​

14. Lee SM, Jeong EM, Jeong J, Shin DM, Lee HJ, Kim HJ, Lim J, Lee JH, Cho SY, Kim MK, Wee WR, Lee JH*, Kim IG*. Cysteamine prevents the development of lens opacity in a rat model of selenite-induced cataract. Invest Ophthalmol Vis Sci. 2012 Mar 15;53(3):1452-9.

​

2010

13. Cho SY, Lee JH, Bae HD, Jeong EM, Jang GY, Kim CW, Shin DM, Jeon JH, Kim IG*. Transglutaminase 2 inhibits apoptosis induced by calcium- overload through down-regulation of Bax. Exp Mol Med. 2010 Sep 30;42(9):639-50.

​

12. Cho SY, Jeon JH, Kim CW, Shin DM, Jang GY, Jeong EM, Lee SE, Song KY, Kim IG*. Monoclonal antibodies to human transglutaminase 4. Hybridoma (Larchmt). 2010 Jun;29(3):263-7.

​

11. Cho SY, Choi K, Jeon JH, Kim CW, Shin DM, Lee JB, Lee SE, Kim CS, Park JS, Jeong EM, Jang GY, Song KY, Kim IG*. Differential alternative splicing of human transglutaminase 4 in benign prostate hyperplasia and prostate cancer. Exp Mol Med. 2010 Apr 30;42(4):310-8.

​

2009

10. Jeong EM, Kim CW, Cho SY, Jang GY, Shin DM, Jeon JH, Kim IG*. Degradation of transglutaminase 2 by calcium-mediated ubiquitination responding to high oxidative stress. FEBS Lett. 2009 Feb 18;583(4):648-54.

​

2008

9. Shin DM, Jeon JH, Kim CW, Cho SY, Lee HJ, Jang GY, Jeong EM, Lee DS, Kang JH, Melino G, Park SC, Kim IG*. TGFbeta mediates activation of transglutaminase 2 in response to oxidative stress that leads to protein aggregation. FASEB J. 2008 Jul;22(7):2498-507.

​

2006

8. Choi H, Cho SY, Schwartz RH, Choi K*. Dual effects of Sprouty1 on TCR signaling depending on the differentiation state of the T cell. J Immunol. 2006 May 15;176(10):6034-45.

​

7. Jeon JH, Kim CW, Shin DM, Cho SY, Jang GY, Lee HJ, Kim IG*. Colorimetric transglutaminase assays combined with immunological signal amplification. Anal Biochem. 2006 Jan 15;348(2):327-9.

​

6. Jeon JH, Cho SY, Kim CW, Shin DM, Jang GY, Lee HJ, Kang HS, Park SC, Kim IG*. Alteration of Rb binding to HPV 18 E7 modified by transglutaminase 2 with different type of polyamines. Front Biosci. 2006 May 1;11:1540-8.

​

2005

5. Jeon JH, Lee HJ, Jang GY, Kim CW, Shim DM, Cho SY, Yeo EJ, Park SC, Kim IG*. Different inhibition characteristics of intracellular transglutaminase activity by cystamine and cysteamine. Exp Mol Med. 2004 Dec 31;36(6):576-81.

​

2004

4. Jeon JH, Jang GY, Kim CW, Shin DM, Cho SY, Kwon JC, Lee HJ, Choi KH, Kim IG*. Cell-based assay for monitoring transglutaminase activity. Anal Biochem. 2004 Oct 15;333(2):399-401.

​

3. Shin DM, Jeon JH, Kim CW, Cho SY, Kwon JC, Lee HJ, Choi KH, Park SC, Kim IG*. Cell type-specific activation of intracellular transglutaminase 2 by oxidative stress or ultraviolet irradiation: implications of transglutaminase 2 in age-related cataractogenesis. J Biol Chem. 2004 Apr 9;279(15):15032-9.

​

2003

2. Jeon JH, Choi KH, Cho SY, Kim CW, Shin DM, Kwon JC, Song KY, Park SC, Kim IG. Transglutaminase 2 inhibits Rb binding of human papillomavirus E7 by incorporating polyamine. EMBO J. 2003 Oct 1;22(19):5273-82.

​

2002

1. Jeon JH, Cho SY, Kim CW, Shin DM, Kweon JC, Choi KH, Park SC, Kim IG*. GTP is required to stabilize and display transamidation activity of transglutaminase 2. Biochem Biophys Res Commun. 2002 Jun 21;294(4):818-22.

​

​

​